$17.81
▲ +$1.21
(+7.29%)
Vol 5.5M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.1B
ROE
-33.1%
D/E
0.00
Beta
1.19
52W
$1–$4
Wall Street Consensus
17 analysts · Apr 20265
Strong Buy
9
Buy
2
Hold
1
Sell
0
Strong Sell
82.4%
Buy Rating
Price Chart
Similar Stocks
SRRK
Scholar Rock Holding Corp
$4.5B
COGT
Cogent Biosciences Inc
$5.4B
CGON
CG Oncology Inc
$3.3B
MIRM
Mirum Pharmaceuticals Inc
$4.1B
PTCT
PTC Therapeutics Inc
P/E 8.1
$6.1B
CAI
Caris Life Sciences Inc
$7.6B
CELC
Celcuity Inc
$4.6B
TGTX
TG Therapeutics Inc
P/E 10.6
$4.7B
APLS
Apellis Pharmaceuticals Inc
P/E 70.7
$3.2B
IMVT
Immunovant Inc
$5.1B
Earnings
Beat rate: 50.0%
Next Report
May 11, 2026
EPS Estimate: $-0.21
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.21 | — | — |
| Dec 2025 | $-0.11 | $-0.10 | +$0.01 |
| Sep 2025 | $-0.11 | $-0.11 | $0.00 |
| Jun 2025 | $-0.11 | $-0.12 | $-0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | — | -$32.2M | -$31.0M | -$33.9M | -$30.6M | -$29.1M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -31.2% | -36.6% | -31.2% | -31.2% | -31.2% | -33.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 11.04 | 12.35 | 11.04 | 11.04 | 11.04 | 10.45 |
Key Ratios
ROA (TTM)
-27.8%
P/B
1.7
EPS (TTM)
$-0.45
CF/Share
$-1.57
52W High
$3.80
52W Low
$1.01
$1.01
52-Week Range
$3.80
Financial Health
Free Cash Flow
-$21.7M
Net Debt
-$26.7M
Cash
$73.8M
Total Debt
$47.1M
As of Dec 31, 2025
How does ERAS compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ERAS valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.7
▼
32%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ERAS profitability vs Biotechnology peers
ROE
-33.1%
▲
51%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-27.8%
▲
41%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
ERAS financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
10.5
▲
135%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.2
▲
23%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
ERAS fundamentals radar
ERAS
Peer median
Industry
ERAS profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ERAS vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
MORRIS SHANNON R. M.D., PH.D.
Officer · Mar 04
20000 shs
MORRIS SHANNON R. M.D., PH.D.
Officer · Mar 04
20000 shs
GARNER EBUN S
General Counsel · Jan 07
120000 shs
GARNER EBUN S
General Counsel · Jan 07
120000 shs
Last 90 days
Top Holders
Top 5: 27.93%Frazier Life Sciences Manag…
7.31%
$340.3M
VR Adviser, LLC
5.75%
$267.3M
T. Rowe Price Investment Ma…
5.18%
$241.2M
Blackrock Inc.
5.02%
$233.5M
Suvretta Capital Management…
4.67%
$217.1M
As of Dec 31, 2025